Oxford
Oxford
Oxford, UK, United Kingdom2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 | 2026-10-09 | NCT06343805 | |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoid syndrome, carcinoid tumor, carcinoma, cecum neuroendocrine tumor G1, enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor, epithelial neoplasm, ileal neuroendocrine tumor G1, intestinal neuroendocrine tumor G1, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, serotonin syndrome | Recruiting | Phase 3 | 2026-09-15 | NCT07087054 |